Woodmont Investment Counsel’s Biostage, Inc. Common Stock BSTG Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2017
Q4 | – | Sell |
-22,500
| Closed | -$7K | – | 193 |
|
|
2017
Q3 | $7K | Hold |
22,500
| – | – | ﹤0.01% | 183 |
|
|
2017
Q2 | $9K | Sell |
22,500
-37,100
| -62% | -$11.8K | ﹤0.01% | 181 |
|
|
2017
Q1 | $53K | Hold |
59,600
| – | – | 0.02% | 182 |
|
|
2016
Q4 | $53K | Sell |
59,600
-123,549
| -67% | -$110K | 0.02% | 185 |
|
|
2016
Q3 | $197K | Buy |
183,149
+10,000
| +6% | +$10.8K | 0.06% | 173 |
|
|
2016
Q2 | $197K | Sell |
173,149
-2,400
| -1% | -$3.87K | 0.06% | 181 |
|
|
2016
Q1 | $314K | Buy |
175,549
+1,500
| +0.9% | +$2.49K | 0.09% | 146 |
|
|
2015
Q4 | $379K | Buy |
174,049
+89,549
| +106% | +$125K | 0.11% | 145 |
|
|
2015
Q3 | $72K | Buy |
84,500
+24,500
| +41% | +$27.8K | 0.02% | 238 |
|
|
2015
Q2 | $86K | Hold |
60,000
| – | – | 0.02% | 228 |
|
|
2015
Q1 | $195K | Buy |
60,000
+16,297
| +37% | +$55.5K | 0.06% | 165 |
|
|
2014
Q4 | $139K | Buy |
43,703
+23,620
| +118% | +$117K | 0.04% | 164 |
|
|
2014
Q3 | $163K | Hold |
20,083
| – | – | 0.05% | 195 |
|
|
2014
Q2 | $210K | Hold |
20,083
| – | – | 0.06% | 192 |
|
|
2014
Q1 | $182K | Hold |
20,083
| – | – | 0.05% | 194 |
|
|
2013
Q4 | $95K | Buy |
+20,083
| New | +$93.9K | 0.03% | 192 |
|
Woodmont Investment Counsel's BSTG Position: Q4 2017 in Review
Woodmont Investment Counsel sold out of Biostage, Inc. Common Stock (BSTG) in Q4 2017, closing a stake of 22,500 shares — an estimated $7K sold.
Woodmont Investment Counsel first reported a position in BSTG in Q4 2013 and held it in 16 quarters. The position peaked at $379K in Q4 2015. 0 funds tracked by Wall St. Rank hold BSTG as of Q4 2017.
- Woodmont Investment Counsel reported no remaining Biostage, Inc. Common Stock position as of Q4 2017 after selling out during the quarter.
- Woodmont Investment Counsel sold 22,500 Biostage, Inc. Common Stock shares in Q4 2017, an estimated $7K.
- Woodmont Investment Counsel first reported a position in Biostage, Inc. Common Stock in Q4 2013 and held it in 16 quarters.
- Woodmont Investment Counsel's Biostage, Inc. Common Stock position peaked at $379K in Q4 2015.
- 0 funds tracked by Wall St. Rank held Biostage, Inc. Common Stock as of Q4 2017.
Based on Woodmont Investment Counsel's 13F filing for Q4 2017, filed 13 Feb 2018.